Monolayer-Based Wnt-Modulation Differentiation of Human iPSCs into Contracting Ventricular Cardiomyocytes (GiWi Protocol)

Differentiations are run in biological triplicate (3 independent wells per condition, each seeded from a separate passage) across at least 2 independent hiPSC clones to control for line-specific bias. A CHIR99021 dose-response titration (4, 6, 8, 10, 12 µM) is performed per new line on first use to define the optimum. Time points for sampling: day 0 (pluripotent baseline), day 2 (mesoderm: T/BRACHYURY), day 5 (cardiac progenitor: NKX2-5/ISL1), day 8 (early CM), day 15 (mature monolayer). Purity is read out by flow cytometry at day 15 (n=3 wells). Beating onset is scored daily (days 6-12) by two blinded observers. Target seeding density is empirically calibrated to reach 90-100% confluence on day 0.

BSL-2 practices for human pluripotent/derived cell culture; all open work in a Class II biosafety cabinet. CHIR99021, IWP-2, IWR-1, and Y-27632 are biologically active small molecules — handle DMSO stocks with nitrile gloves and avoid skin contact; DMSO is a skin penetration enhancer. Matrigel is a murine sarcoma-derived product (handle as potentially biohazardous). Lactate stock is low hazard. PPE: lab coat, nitrile gloves, safety glasses. Liquid biohazard waste is bleached (final 10% v/v, 30 min) before disposal; solid waste is autoclaved. hiPSC lines must be used under approved institutional stem-cell oversight (e.g., ESCRO/SCRO) where required.

Negative/undifferentiated control: a parallel well maintained in mTeSR Plus (no CHIR) should remain pluripotent (OCT4+/cTnT-negative) and never beat. Vehicle control: DMSO added at the maximal carrier volume used for CHIR/IWP-2 (<0.2% v/v) confirms the phenotype is small-molecule-driven, not solvent toxicity. Positive differentiation control: a previously validated 'good-batch' hiPSC clone run in the same experiment anchors expected yield. Flow cytometry controls: unstained, viability-only, and isotype-matched APC mouse IgG to set the cTnT gate. Metabolic-selection control: an unselected well processed in parallel to quantify purity gain attributable to lactate selection.

A robust differentiation shows visible mesodermal sheet detachment-and-reattachment around days 2-4, with the first spontaneous contractions of synchronized patches by day 8-10. Flow cytometry at day 15 should yield 60-95% cTnT+ cells pre-selection and >90% after lactate purification. Beating monolayers should display rhythmic, synchronous contraction at ~0.5-1.5 Hz. Yields typically range 2-6 cardiomyocytes per input hiPSC. qPCR should show TNNT2, MYH6, NKX2-5, and TNNI3 induction with concurrent OCT4/NANOG silencing by day 8.

• Human iPSC line (e.g., WTC-11 or a validated patient line), mycoplasma-negative, karyotype-normal, passage <50
• mTeSR Plus or Essential 8 maintenance medium
• Growth factor-reduced Matrigel (Corning 354230), aliquoted, diluted 1:60 in cold DMEM/F-12
• RPMI 1640 medium (no glucose variant for selection: RPMI 1640 without glucose)
• B-27 supplement minus insulin (Gibco A1895601) for days 0-7
• B-27 supplement complete (Gibco 17504044) for day 7 onward
• CHIR99021 (GSK3β inhibitor), 10 mM stock in DMSO; working 4-12 µM
• IWP-2 (Wnt inhibitor), 5 mM stock in DMSO; working 5 µM (or IWR-1 5 µM)
• ROCK inhibitor Y-27632, 10 mM stock; working 10 µM (seeding day only)
• Accutase or Versene (0.5 mM EDTA) for passaging
• Sodium DL-lactate (for metabolic selection), 1 M stock, working 4 mM in glucose-free RPMI
• Anti-cTnT antibody (clone 13-11, Thermo MA5-12960) + APC anti-mouse secondary; viability dye (eFluor 780)

To reproducibly differentiate human induced pluripotent stem cells (hiPSCs) into spontaneously beating ventricular-like cardiomyocytes (CMs) using the chemically defined GiWi monolayer method, which sequentially activates (CHIR99021) then inhibits (IWP-2/IWR-1) canonical Wnt signaling. The endpoint is a metabolically selectable population yielding >80% cardiac troponin T (cTnT/TNNT2)-positive cells by day 15, confirmed by flow cytometry and spontaneous contraction onset between days 8-10.

1. Day -3 to -1: Seed dissociated hiPSCs as single cells onto Matrigel-coated 12-well plates at 1.5-3 x10^5 cells/well in mTeSR Plus + 10 µM Y-27632; refresh medium daily without ROCKi. Aim for 90-100% confluent uniform monolayer on day 0.
2. Day 0: Aspirate; add 2 mL/well RPMI + B-27 minus insulin + CHIR99021 at the line-optimized dose (start 6 µM). Note exact time.
3. Day 2 (exactly 48 h later): Replace with 2 mL RPMI + B-27 minus insulin (NO CHIR). Cells will appear stressed/sparse — this is expected.
4. Day 3: Combine 1 mL conditioned (spent) medium with 1 mL fresh RPMI + B-27 minus insulin containing IWP-2 to a final 5 µM. Add to well (total 2 mL).
5. Day 5: Replace with 2 mL fresh RPMI + B-27 minus insulin (no inhibitors).
6. Day 7: Switch to 2 mL RPMI + B-27 complete (with insulin). Refresh every 2-3 days.
7. Days 8-10: Observe spontaneous contraction. Record beating onset day per well.
8. Day 11-15 (optional purification): Switch to glucose-free RPMI + 4 mM lactate for 3-4 days to metabolically eliminate non-CMs; then return to RPMI + B-27 complete to recover.
9. Day 15: Dissociate a well with 10x TrypLE (10 min, 37°C), fix/permeabilize, stain for cTnT, and acquire on a flow cytometer to quantify purity.

Independent variables: CHIR99021 concentration (4-12 µM), seeding density, and Wnt-inhibitor timing (day 3 vs day 4). Dependent variables: % cTnT+ cells (flow), beating onset day, beating area fraction, and viable cell yield per cm². Controlled variables: medium lot (single lot per experiment), Matrigel lot and coating time, passage number window (<50), incubator CO2 (5%)/O2 (atmospheric)/temperature (37°C), exact 48 h CHIR exposure window, and operator (single operator per differentiation run).

Precise temporal biphasic modulation of Wnt/β-catenin signaling — GSK3β inhibition (mesoderm induction) on days 0-2 followed by Wnt secretion inhibition (cardiac specification) on days 3-5 — will direct a confluent hiPSC monolayer toward the cardiac mesoderm lineage, producing functional cardiomyocytes at higher purity and lower cost than embryoid-body or growth-factor-based methods. We predict CHIR99021 concentration is the dominant determinant of yield, with an optimum near 6-12 µM that is line-dependent.

Flow cytometry .fcs files are analyzed in FlowJo: gate on FSC/SSC (singlets), exclude dead cells (eFluor 780+), then quantify %cTnT+ against the isotype gate. Beating onset and beating-area fraction are scored from 10x phase-contrast videos; area fraction is quantified in ImageJ by motion-vector or pixel-variance over a 10 s clip. qPCR Cq values are normalized to GAPDH and a day-0 reference using the 2^-ΔΔCt method. Dose-response yield curves are fit to a log-normal peak model to estimate the optimal CHIR concentration per line.

1. No beating by day 12: usually wrong CHIR dose or confluence — re-titrate CHIR (±2 µM) and ensure 90-100% confluence on day 0; over-confluent or sparse monolayers fail. 2. Massive cell death days 2-4: expected to a degree, but excessive loss means CHIR too high or 48 h window overshot — shorten exposure to exactly 48 h and lower CHIR. 3. Low purity (<50%) at day 15: add/extend lactate metabolic selection and verify B-27 'minus insulin' was used days 0-7 (insulin too early suppresses cardiac yield). 4. Patchy/asynchronous beating: typical of immaturity or uneven seeding; replate at higher density and culture longer (day 20+). 5. Contamination/mycoplasma: re-test the line; mycoplasma silently collapses differentiation efficiency.

Purity across CHIR doses is compared by one-way ANOVA with Tukey's HSD post-hoc correction (α=0.05), using n=3 biological replicates per dose and reporting mean ± SD. Two-line comparisons of optimized yield use a two-tailed unpaired t-test or Mann-Whitney if non-normal (Shapiro-Wilk pre-test). A priori power analysis (G*Power) for detecting a 15 percentage-point purity difference at SD≈8%, α=0.05, power=0.8 indicates n=6 wells/group; we therefore replicate across ≥2 independent passages. The dose-optimum CI is estimated by bootstrap (1000 resamples).